What Laboratorios Alfa does

Laboratorios Alfa is a Dominican Republic-based pharmaceutical manufacturer founded in 1976 by engineer Alejandro Farach and operating as a subsidiary of the diversified conglomerate Grupo Farach. The company manufactures and distributes a portfolio of more than 1,000 generic and branded pharmaceutical products across multiple therapeutic categories — including cardiovascular, anti-infective, dermatological, respiratory, gastrointestinal, and central nervous system — in dosage forms ranging from tablets, capsules, syrups, and topical preparations to injectables, sera, and respiratory ampoules.

Production is concentrated across two purpose-built plants in the Dominican Republic: Planta Alfa I (11,505 m²) handles solid and semi-solid dose manufacturing with stated monthly capacity exceeding 70 million tablets/capsules, 3 million topical units, and 900,000 bottles of syrups, operating under BPM standards with an on-site quality control and microbiology laboratory and a dedicated R&D function; Planta Alfa II, operational since 2009, uses German-technology machinery to produce sera and small- and large-volume parenterals. A third line, the Unidosis ampoule facility launched in 2021 with an investment exceeding RD$300 million, produces respiratory therapy nebulizer ampoules at more than 34,000 units per hour and is, per company claims, the only such domestic manufacturer in the Dominican Republic. Combined manufacturing footprint is 22,000 m².

The company sells primarily through traditional B2B pharmaceutical channels — retail pharmacies, institutional/hospital channels, and export distributors — across the Dominican Republic and ten countries in Central America, the United States, and South America. Pricing is not publicly disclosed and is handled via direct sales contacts (WhatsApp/email) and likely institutional procurement. Brand-led engagement with healthcare professionals is conducted through medical congress sponsorships and training workshops, including postpartum hemorrhage workshops co-organized with the Dominican Ministry of Public Health, the National Health System, INTEC, the Dominican Medical College, and SDOG. Laboratorios Alfa holds the #1 position in unit sales in the Dominican Republic pharmaceutical market and was recognized in 2020 as the most admired company in the pharmaceutical laboratories category by Revista Mercado.

Name

Laboratorios Alfa

Legal name

Laboratorios Alfa

Website

https://laboratoriosalfa.com

Company type

Private

Founded year

1976

Operating status

Operating

Headcount range

251–500 employees

Short description

Laboratorios Alfa is a Dominican Republic pharmaceutical manufacturer (founded 1976, Grupo Farach subsidiary) that produces 1,000+ generic and branded medicines across two plants totaling 22,000 m², holding the #1 unit-sales position domestically and exporting to 10 countries in the Americas.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541), Medicinal and Botanical Manufacturing (325411)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Generic Hospital & Institutional Products (HLAIABAL)

akta.pro secondary industry

Sterile Injectable Generics (HLAIABAC)

Keywords

• Pharmaceutical manufacturing
• Generic medicines
• Branded pharmaceuticals
• Cardiovascular medications
• Respiratory therapy ampoules

Headquarters

HQ city

Santo Domingo

HQ country

Dominican Republic

HQ region

Latin America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Pharmaceutical Product Sales: Laboratorios Alfa generates revenue primarily through the manufacture and sale of pharmaceutical products including generic and branded medications across multiple therapeutic categories (cardiovascular, anti-infective, dermatological, respiratory, gastrointestinal, central nervous system, etc.) and multiple dosage forms (tablets, capsules, powders, syrups, creams, ointments, injectables, sera, suppositories, and ampoules). Products are sold through pharmacies and healthcare providers across the Dominican Republic and exported to 10 countries in Central America, the US, and South America. The company operates both generic (Generico) and branded (Marcas) product lines.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

Laboratorios Alfa manufactures and distributes generic and branded pharmaceutical products across multiple therapeutic categories including cardiovascular, anti-infective, dermatological, respiratory, gastrointestinal, and central nervous system medications. The company operates two production plants (Alfa I for solid/semi-solid forms; Alfa II for parenterals and sera) and a Unidosis line for respiratory therapy nebulizer ampoules, producing over 1,000 products distributed across the Dominican Republic and 10 countries in Central America, the US, and South America.

Product overview

Laboratorios Alfa is a pharmaceutical company offering a comprehensive portfolio of over 1,000 generic and branded pharmaceutical products. The product portfolio includes branded products (Aspiren, Avantar, Capsartan, Carbaline, Cardialec-A, Carditran, Dermitella, Enzitina, Furolax, Latimax, Lisitrol) alongside an extensive generic pharmaceutical line covering antibiotics, cardiovascular medications, pain relievers, respiratory treatments, and dermatological products. The company operates two manufacturing plants (Alfa I and Alfa II) plus a dedicated Unidosis line for respiratory therapy ampoules, making them the largest and most modern pharmaceutical laboratory in the Antilles.

Differentiator

Problem solved

Functional benefit

Brands

• Alfa I: Primary production plant for pharmaceutical products including tablets, capsules, powders, and creams.
• Alfa II
• Unidosis

Products and services

• Aspiren
• Avantar Brand-name Losartan-based product line for hypertension treatment, available in 50mg, 100mg dosages, and combination formulas (A, Plus, Ultra variants).
• Capsartan Brand-name angiotensin receptor blocker (ARB) containing Candesartan for hypertension treatment, available in 8mg, 16mg, and 32mg dosages.
• Carbaline Brand-name product line containing Carvedilol for hypertension and cardiovascular conditions, available in multiple dosages and combination formulas.
• Cardialec-A Brand-name combination product with Atenolol, Amlodipine, and Chlorthalidone for cardiovascular treatment.
• Carditran Brand-name product line with Irbesartan for hypertension treatment, available in various combinations with Amlodipine or Hydrochlorothiazide.
• Dermitella Dermatological product line including antibiotics and cicatrizantes for treating various skin conditions, promoted as a tissue regenerator and wound healing product.
• Enzitina Brand-name statin product containing Atorvastatin for cholesterol management, available in 20mg, 40mg, and 80mg dosages.
• Furolax Brand-name diuretic product containing Furosemide for fluid retention and edema treatment.
• Latimax Brand-name ACE inhibitor product containing Ramipril for hypertension treatment, available in multiple dosages and combination formulas.
• Lisitrol Brand-name ACE inhibitor product containing Lisinopril for hypertension treatment, available in various combinations with Amlodipine or Hydrochlorothiazide.
• Generic Pharmaceutical Portfolio Extensive portfolio of over 1,000 generic pharmaceutical products including antibiotics (Amoxicillin, Azithromycin, Ciprofloxacin, Levofloxacin), cardiovascular medications (Bisoprolol, Enalapril, Losartan, Metoprolol), pain relievers (Diclofenac, Ibuprofen, Tramadol), and other therapeutic categories.
• Unidosis Respiratory Therapy Ampoules Respiratory therapy nebulizer ampoules manufactured via the Unidosis line, with production capacity of 34,000+ units per hour and monthly output of 3.5 million ampoule units. Laboratorios Alfa is the only manufacturer of respiratory therapy ampoules in the Dominican Republic.

Quantifiable outcome

• The only manufacturer of respiratory therapy nebulizer ampoules in the Dominican Republic
• +1 more outcomes

Named customers6 records

Segments3 records

Ideal customer profiles5 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Six partnerships are on record, tiered core.

• Ministerio de Salud Pública de República DominicanacoreStrategic or Co-development Partner · 1 January 2022Laboratorios Alfa collaborated with the Dominican Ministry of Public Health to organize and sponsor training workshops on postpartum hemorrhage for physicians and obstetricians. The workshops aimed to strengthen professional competencies to reduce maternal mortality rates in the country. The Minister of Health presided over the inaugural event.
• Sistema Nacional de Salud (SNS)coreStrategic or Co-development Partner · 1 January 2022Laboratorios Alfa partnered with the National Health System (SNS) alongside Salud Pública, the Dominican Medical College, and INTEC to deliver professional medical training workshops on postpartum hemorrhage. The initiative involved both national and international medical experts.
• Colegio Médico DominicanocoreStrategic or Co-development Partner · 1 January 2022Laboratorios Alfa collaborated with the Dominican Medical College as part of the institutional cooperation framework for medical training workshops on postpartum hemorrhage, with the goal of reducing maternal mortality through physician education.
• Instituto Tecnológico de Santo Domingo (INTEC)coreStrategic or Co-development Partner · 1 January 2022Laboratorios Alfa partnered with INTEC (Technological Institute of Santo Domingo) in an institutional cooperation approach to deliver postpartum hemorrhage training workshops for medical professionals alongside the Ministry of Health and other healthcare bodies.
• Sociedad de Obstetricia y Ginecología (SDOG)coreStrategic or Co-development Partner · 1 January 2022Laboratorios Alfa organized training workshops on postpartum hemorrhage jointly with SDOG, the Dominican Society of Obstetrics and Gynecology. SDOG's president participated in the inaugural ceremony alongside the Minister of Health and other authorities. The workshops featured Mexican specialists Francisco Zea and Alejandro Posadas presenting the Zea and Posadas techniques.
• Grupo FarachcoreOthers · 1 January 2022Laboratorios Alfa is a wholly-owned subsidiary of Grupo Farach, a diversified industrial group with 50+ years of history in the Dominican Republic and now operating regionally and internationally. Grupo Farach produces, distributes, and commercializes mass consumer and premium products in the pharmaceutical, hospital, and health and beauty services industries through Laboratorios Alfa, Cofaca, and Plastifar. Grupo Farach has 2,500+ direct employees and 5,000+ indirect employees.

Scale indicators8 records

Recent moves5 records

Expansion highlights5 records

Broad incumbents

• Aurobindo Pharma: Indian-headquartered global generic pharmaceutical manufacturer with significant operations in the US, Europe, and emerging markets. Comparable in vertical integration of API and finished-dose generics manufacturing, and a direct competitor in Latin American institutional and retail channels.
• Sandoz Group: Global generics leader spun off from Novartis, with extensive operations in Latin America and the Caribbean. Represents the multinational generics competition Laboratorios Alfa faces in export markets, with substantially broader portfolio, regulatory footprint, and pricing power.
• Teva Pharmaceutical Industries: World's largest generic drug manufacturer with deep presence across the Americas. Competes with Laboratorios Alfa in the generics space through its broad portfolio of sterile injectables, oral solids, and consumer health products across Latin American markets.
• Bayer (Pharmaceutical Division): Global pharmaceutical and consumer health major with established commercial infrastructure across the Dominican Republic, Central America, and South America. Represents the multinational competition in cardiovascular, anti-infective, and OTC categories where Laboratorios Alfa's branded portfolio overlaps.

Direct peers

• Laboratorios Lam: Dominican Republic-based pharmaceutical manufacturer offering a portfolio of branded and generic products across similar therapeutic categories. Directly comparable as a national DR pharmaceutical peer of similar scale competing for institutional and retail pharmacy contracts.
• Laboratorios Magnachem: Dominican Republic pharmaceutical company with a diversified branded and generic product portfolio. Comparable in market positioning, channel mix (pharmacies and institutional), and therapeutic category breadth within the DR market.

Regional players

• Eurofarma Laboratórios: Brazilian pharmaceutical manufacturer with a strong generics, branded generics, and hospital portfolio, expanding aggressively across Latin America including Central America and the Caribbean. Comparable business model (multi-dosage form manufacturing, generic and branded generics, institutional channel focus) and competitive overlap in LatAm export markets.
• Genfar: Sanofi-owned Latin American generics manufacturer headquartered in Colombia, with broad presence across the Andean region and Central America. Comparable as a regional branded-generics player with a multi-country distribution footprint targeting similar institutional and retail channels.
• Genomma Lab Internacional: Mexico-based pharmaceutical and personal care company with broad Latin American distribution across 20+ countries. Comparable in leveraging branded generics strategy with strong commercial execution and adjacent OTC categories in the same regional markets Laboratorios Alfa targets.
• Grupo Difare: Ecuador-based pharmaceutical and consumer health group with manufacturing and distribution across multiple Latin American countries. Comparable in operating as a vertically integrated regional pharma manufacturer-distributor competing for generics share across LatAm.

Market position

Strengths1 record

Weaknesses1 record

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCJ-nk9HxWlb8PXFV9NlKo-A
• Facebookes-la.facebook.com/people/Laboratorios-Alfa/100056235273782
• LinkedInlinkedin.com/company/farach-s.a.
• Instagraminstagram.com/laboratoriosalfard/?hl=es

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Laboratorios Alfa